Skip to content

PROvide MIner-friendly SErvices for Integrated TB/HIV Care in Lesotho Study

PROvide MIner-friendly SErvices for Integrated TB/HIV Care in Lesotho Study (PROMISE Study)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03537872
Acronym
PROMISE
Enrollment
248
Registered
2018-05-25
Start date
2018-03-13
Completion date
2019-12-31
Last updated
2023-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV

Brief summary

The PROvide MIner-friendly SErvices for Integrated TB/HIV Care (PROMISE) study will assess the effectiveness, feasibility, and acceptability of integrated tuberculosis (TB)/HIV services provided in miner-friendly service venues in Lesotho that address barriers to early HIV diagnosis and antiretroviral therapy (ART) initiation, concurrent isoniazid preventive therapy (IPT), and retention in HIV care for migrant miners and their families in the context of President's Emergency Plan For AIDS Relief (PEPFAR) programming. The study will evaluate family-focused, integrated TB/HIV services for Basotho migrant miners and family members provided six days per week in miner-friendly service venues (MF), compared to public sector health facilities (PS), which will deliver usual integrated care for the management of TB and HIV. The ultimate goals of the project are to 1) improve health outcomes among migrant miners and their families, a hard-to-reach population that represents a hotspot of TB/HIV transmission, in Lesotho and in PEPFAR programs more broadly; and 2) strengthen the implementation science research capacity of national and local institutions.

Detailed description

TB is the most common opportunistic infection and a leading cause of death among people living with HIV (PLHIV). Early ART and IPT have been shown to reduce TB incidence, morbidity, and mortality among PLHIV, including those with high CD4 counts, and are recommended by the World Health Organization (WHO) as core strategies to reduce the burden of TB among PLHIV. Basotho migrant miners, who travel between their homes in Lesotho and work in South African mines, and their families are at elevated risk of HIV and TB, however, their testing, engagement, and retention in care and treatment are suboptimal. Implementation science research is urgently needed to determine an effective strategy for improving early detection of HIV and early initiation of ART and IPT among migrant miners and their families. The PROMISE study is a mixed-methods implementation science study that will evaluate a miner-friendly intervention strategy to implement early ART and concurrent IPT for PLHIV. The study will assess the effectiveness, feasibility, and acceptability of integrated TB/HIV services for migrant miners and their family members provided in miner-friendly service venues (MF). A prospective cohort study design will be used to evaluate the effectiveness of family-focused, integrated TB/HIV services for Basotho migrant miners and family members provided six days per week in miner-friendly service venues, compared to public sector health facilities (PS), which will deliver usual integrated care for the management of TB and HIV. All participants will be assessed at the time of HIV testing (baseline), and at months 3, 6, and 9. Through implementing and measuring this enhanced TB/HIV service delivery model for miners and their families, study findings will have important implications on programs and policies broadly for PEPFAR, and specifically in Lesotho, for the organization and delivery of integrated TB/HIV services to migrant miners and their families. Findings will inform the development of more tailored interventions to promote HIV diagnosis, early ART, and IPT among miners with HIV, with possible implications for other types of mobile populations; enhance scientific awareness about the unique challenges facing miners in the context of their migration and high TB/HIV co-morbidity; and guide future efforts to develop differentiated service delivery models and integrated HIV/TB services in populations with a high prevalence of HIV and TB.

Interventions

BEHAVIORALMiner-Friendly (MF) Service Venues TB/HIV Integration Strategies

In addition to the control condition strategies (marked PS), the MF intervention includes additional strategies (marked MF): STRUCTURAL LEVEL Co-location of TB and HIV services (PS); Co-location of clinical and non-clinical services (MF); Demand creation (MF); Weekend service hours (MF) CLINIC LEVEL Intensified TB case finding and IPT (PS); Test and START (PS); Training for healthcare workers (PS); Job aids and mentorship for healthcare workers (MF) INDIVIDUAL/FAMILY LEVEL Health literacy for patients (PS); Family counseling (PS - limited); One-way SMS text messaging and lay counselor support for adherence and retention (MF); A menu of options for medication refills for miners unable to visit the clinic on a monthly basis (MF)

BEHAVIORALPublic Sector (PS) Health Facilities TB/HIV Integration Strategies

STRUCTURAL LEVEL Co-location of TB and HIV services CLINIC LEVEL Intensified TB case finding and IPT; Test and START; Training for healthcare workers INDIVIDUAL/FAMILY LEVEL Health literacy for patients; Family counseling (limited); Adherence support from nurses and village health workers

Sponsors

Centers for Disease Control and Prevention
CollaboratorFED
Ministry of Health, Lesotho
CollaboratorOTHER_GOV
National University of Lesotho (NUL)
CollaboratorUNKNOWN
Columbia University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

MF Cohort Inclusion Criteria: * Tested HIV-positive at MF site within one week of study enrollment * Currently working or have worked in a South African mine, or are a family member of a miner (first-degree relative) * Not on ART or IPT prior to testing HIV positive at the study site within the past week * No history of IPT use * 15 years or older * Basotho origin * Capacity for consent MF Cohort

Exclusion criteria

* Active TB * Unwilling to provide a phone number or adhere to study procedures PS Cohort Inclusion Criteria: * Tested HIV-positive at either the OPD or voluntary counseling and testing (VCT) clinic on-site within one week of study enrollment * Not on ART or IPT prior to testing HIV positive at the study site within the past week * No history of IPT use * 15 years or older * Basotho origin * Capacity for consent PS Cohort

Design outcomes

Primary

MeasureTime frameDescription
Proportion of newly diagnosed HIV-positive participants initiated on ART (ART Initiation)Up to 3 weeks after 9-month interviewParticipants will complete interviewer-administered questionnaires and data will be abstracted from their medical records to assess ART initiation. This is designed to determine if participants at MF are more likely to initiate ART compared to those at PS.
Proportion of newly diagnosed HIV-positive participants on ART initiated on IPT (IPT initiation)Up to 3 weeks after 9-month interviewParticipants will complete interviewer-administered questionnaires and data will be abstracted from their medical records to assess IPT initiation. This is designed to compare if participants on ART at MF are more likely to initiate IPT compared to those at PS.

Secondary

MeasureTime frameDescription
Time to IPT initiationUp to 3 weeks after 9-month interviewTime to IPT initiation (in days) among newly diagnosed HIV-positive participants. Participants will complete interviewer-administered questionnaires and data will be abstracted from their medical records to assess IPT initiation date.
Proportion of newly diagnosed HIV-positive participants initiated on ART retained in care at 6 and 9 months at original clinicUp to 3 weeks after 9-month interviewART retention, collected from medical records.
Proportion of newly diagnosed HIV-positive participants initiated on ART with plasma viral load <1000 copies/ml at 6 months after ART initiationUp to 3 weeks after 9-month interviewViral suppression, collected from medical records.
CD4 count at enrollmentUp to 3 weeks after 9-month interviewCD4 count at enrollment in care, collected from medical records.
Percentage of total prescribed doses of ART ingested, by self-report, averaged across study visitsUp to 9 months post baseline interviewParticipants will complete interviewer-administered questionnaires to assess ART adherence.
Percentage of positive IsoScreen tests at the first study visit after IPT initiationUp to 9 months post baseline interviewParticipants will submit a urine sample which will be used to perform a IsoScreen test
Percentage of total prescribed doses of IPT ingested, by self-report, averaged across study visitsUp to 9 months post baseline interviewParticipants will complete interviewer-administered questionnaires to assess IPT adherence.
Proportion of participants completed IPT among those who initiated IPTUp to 3 weeks after 9-month interviewIPT completion, collected from medical records.
Time to ART initiationUp to 3 weeks after 9-month interviewTime to ART initiation (in days) among newly diagnosed HIV-positive participants. Participants will complete interviewer-administered questionnaires and data will be abstracted from their medical records to assess ART initiation date.

Countries

Lesotho

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026